With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, metabolic dysfunction-associated non-alcoholic fatty liver disease has become the most prevalent chronic liver disease. This condition frequently occurs in Chinese patients with alcoholic liver disease and chronic hepatitis B. To address the impending public health crisis of non-alcoholic fatty liver disease and its underlying metabolic issues, the Chinese Society of Hepatology and the Chinese Medical Association convened a panel of clinical experts to revise and update the "Guideline of prevention and treatment of non-alcoholic fatty liver disease (2018, China)". The new edition, titled "Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (Version 2024)", offers comprehensive recommendations on key clinical issues, including screening and monitoring, diagnosis and evaluation, treatment, and follow-up for metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatotic liver disease. Metabolic dysfunction-associated fatty liver disease is now the preferred English term and is used interchangeably with metabolic dysfunction-associated steatotic liver disease. Additionally, the guideline emphasizes the importance of multidisciplinary collaboration among hepatologists and other specialists to manage cardiometabolic disorders and liver disease effectively.

随着肥胖、代谢综合征和2型糖尿病在中国的流行，代谢功能障碍相关的非酒精性脂肪性肝病已成为最常见的慢性肝病。为解决非酒精性脂肪性肝病迫在眉睫的公共卫生危机及其潜在的代谢问题，中国肝病学会和中华医学会召集了临床专家小组，修订和更新了《非酒精性脂肪性肝病防治指南（2018，中国）》。新版《代谢功能障碍相关脂肪性肝病防治指南（2024版）》就关键临床问题提供了全面建议，包括代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝病的筛查和监测、诊断和评估、治疗和随访。代谢功能障碍相关的脂肪性肝病现在是首选的英文术语，与代谢功能障碍相关的脂肪性肝病互换使用。此外，该指南强调肝病学家和其他专家之间多学科合作的重要性，以有效地管理心脏代谢紊乱和肝脏疾病。